Literature DB >> 15381503

Lung inflammation as a therapeutic target in cystic fibrosis.

David R Koehler1, Gregory P Downey, Neil B Sweezey, A Keith Tanswell, Jim Hu.   

Abstract

Cystic fibrosis (CF) lung disease is characterized by chronic neutrophilic inflammation and infection. Effective management of airway inflammation could complement other therapies for the treatment of CF. Recent progress has been made in understanding the signaling pathways regulating inflammatory cytokines in the lung. Here we examine the mechanisms responsible for inflammation in the CF lung, and discuss potential therapeutic strategies targeting inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381503     DOI: 10.1165/rcmb.2004-0124TR

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  33 in total

Review 1.  New insights into pulmonary inflammation in cystic fibrosis.

Authors:  S Rao; J Grigg
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

Review 2.  Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator.

Authors:  James F Collawn; Lianwu Fu; Rafal Bartoszewski; Sadis Matalon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-07-25       Impact factor: 5.464

3.  Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells.

Authors:  Cristina Cigana; Baroukh Maurice Assael; Paola Melotti
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

4.  Inflammatory markers of lung disease in adult patients with cystic fibrosis.

Authors:  Hara Levy; Leslie A Kalish; Ian Huntington; Nathaniel Weller; Craig Gerard; Edwin K Silverman; Juan C Celedón; Gerald B Pier; Scott T Weiss
Journal:  Pediatr Pulmonol       Date:  2007-03

5.  Control the platelets, control the disease: A novel cystic fibrosis hypothesis.

Authors:  Siobhan Branfield; A Valance Washington
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

6.  Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells.

Authors:  Florence Borot; Diane-Lore Vieu; Grazyna Faure; Janine Fritsch; Julien Colas; Sandra Moriceau; Maryvonne Baudouin-Legros; Franck Brouillard; Jesus Ayala-Sanmartin; Lhousseine Touqui; Marc Chanson; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

7.  HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.

Authors:  Douglas Conrad; Angela Wang; Raymond Pieters; Ferdinando Nicoletti; Katia Mangano; Anna M van Heeckeren; Steven K White; James M Frincke; Christopher L Reading; Dwight Stickney; Dominick L Auci
Journal:  J Inflamm (Lond)       Date:  2010-10-30       Impact factor: 4.981

8.  Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis.

Authors:  Amanda J Stolarz; Ryan A Farris; Charla A Wiley; Catherine E O'Brien; Elvin T Price
Journal:  Clin Transl Sci       Date:  2015-08-10       Impact factor: 4.689

9.  A genomewide screen for chronic rhinosinusitis genes identifies a locus on chromosome 7q.

Authors:  Jayant M Pinto; M Geoffrey Hayes; Daniel Schneider; Robert M Naclerio; Carole Ober
Journal:  Laryngoscope       Date:  2008-11       Impact factor: 3.325

10.  Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography.

Authors:  Delphine L Chen; Thomas W Ferkol; Mark A Mintun; Jessica E Pittman; Daniel B Rosenbluth; Daniel P Schuster
Journal:  Am J Respir Crit Care Med       Date:  2006-03-16       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.